Premedication as primary prophylaxis does not influence the risk of acute infliximab infusion reactions in immune-mediated inflammatory diseases: A systematic review and meta-analysis.

Affiliation

Gastroenterology, Amiens University Hospital, Université de Picardie Jules Verne, Amiens, France, France. Electronic address: [Email]

Abstract

Up to 25% of patients treated with infliximab experience hypersensitivity reactions. Prophylactic premedication prior to infliximab infusion, comprising corticosteroids and/or antihistamines, is widely used in clinical practice but its efficacy has recently been called into question due to the lack of pathophysiological rationale and validation by controlled trials.

Keywords

IMIDs,Inflammatory bowel disease premedications,Infliximab,

OUR Recent Articles